Literature DB >> 23603558

EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.

Shelly Seward1, Assaad Semaan, Aamer M Qazi, Oksana V Gruzdyn, Sreedhar Chamala, Christopher C Bryant, Sanjeev Kumar, David Cameron, Seema Sethi, Rouba Ali-Fehmi, Robert Morris, David L Bouwman, Adnan R Munkarah, Donald W Weaver, Scott A Gruber, Ramesh B Batchu.   

Abstract

The enhancer of zeste homolog 2 (EZH2) methyltransferase is a transcriptional repressor. EZH2 is abnormally elevated in epithelial ovarian cancer (EOC). We demonstrated that EZH2 knockdown inhibited cell growth, activated apoptosis, and enhanced chemosensitivity. Further, silencing of EZH2 resulted in re-expression of p21(waf1/cip1) and down-regulation of mutant p53. Finally, EZH2 knockdown contributed to attenuated EOC growth in SCID mice. Published by Elsevier Ireland Ltd.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23603558     DOI： 10.1016/j.canlet.2013.04.012

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  19 in total

1.  Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer.

Authors:  Kshipra M Gharpure; Kevin S Chu; Charles J Bowerman; Takahito Miyake; Sunila Pradeep; Selanere L Mangala; Hee-Dong Han; Rajesha Rupaimoole; Guillermo N Armaiz-Pena; Tojan B Rahhal; Sherry Y Wu; J Christopher Luft; Mary E Napier; Gabriel Lopez-Berestein; Joseph M DeSimone; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2014-04-22       Impact factor: 6.261

2.  Expression of EZH2 and P53 and their correlation in ovarian cancer tissues.

Authors:  Li Zhai; Wen-Lin Tai; Yu-Qing Pan; Jian-Bo Luo; Li Ma; Ya-Ting Zheng; Meng-Yue Guo; Xi Zhang
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

3.  Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.

Authors:  Liqiong Cai; Zehua Wang; Denghua Liu
Journal:  Tumour Biol       Date:  2015-12-02

4.  Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia.

Authors:  Qiuhua Zhu; Lingxiu Zhang; Xiaodong Li; Fang Chen; Ling Jiang; Guopan Yu; Zhixiang Wang; Changxin Yin; Xuejie Jiang; Qingxiu Zhong; Hongsheng Zhou; Bingjie Ding; Chunli Wang; Fanyi Meng
Journal:  Tumour Biol       Date:  2016-03-21

5.  Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1.

Authors:  Edwin Choy; Laura E MacConaill; Gregory M Cote; Long P Le; Jacson K Shen; Gunnlaugur P Nielsen; Anthony J Iafrate; Levi A Garraway; Francis J Hornicek; Zhenfeng Duan
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

Review 6.  Histones and their modifications in ovarian cancer - drivers of disease and therapeutic targets.

Authors:  Deborah J Marsh; Jaynish S Shah; Alexander J Cole
Journal:  Front Oncol       Date:  2014-06-12       Impact factor: 6.244

7.  MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2.

Authors:  Yi Zhang; Changwei Lin; Guoqing Liao; Sheng Liu; Jie Ding; Fang Tang; Zhenran Wang; Xingsi Liang; Bo Li; Yangchao Wei; Qi Huang; Xuan Li; Bo Tang
Journal:  Oncotarget       Date:  2015-10-20

8.  Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis.

Authors:  Michel Wassef; Veronica Rodilla; Aurélie Teissandier; Bruno Zeitouni; Nadege Gruel; Benjamin Sadacca; Marie Irondelle; Margaux Charruel; Bertrand Ducos; Audrey Michaud; Matthieu Caron; Elisabetta Marangoni; Philippe Chavrier; Christophe Le Tourneau; Maud Kamal; Eric Pasmant; Michel Vidaud; Nicolas Servant; Fabien Reyal; Dider Meseure; Anne Vincent-Salomon; Silvia Fre; Raphaël Margueron
Journal:  Genes Dev       Date:  2015-12-04       Impact factor: 11.361

9.  Long noncoding RNA HOXA-AS2 promotes gastric cancer proliferation by epigenetically silencing P21/PLK3/DDIT3 expression.

Authors:  Min Xie; Ming Sun; Ya-nan Zhu; Rui Xia; Yan-wen Liu; Jie Ding; Hong-wei Ma; Xue-zhi He; Zhi-hong Zhang; Zhi-jun Liu; Xiang-hua Liu; Wei De
Journal:  Oncotarget       Date:  2015-10-20

10.  Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.

Authors:  Fei-Zhou Jiang; Yin-Yan He; Hui-Hui Wang; Hui-Lin Zhang; Jian Zhang; Xiao-Fang Yan; Xiao-Jun Wang; Qi Che; Jie-Qi Ke; Zheng Chen; Huan Tong; Yong-Li Zhang; Fang-Yuan Wang; Yi-Ran Li; Xiao-Ping Wan
Journal:  Oncotarget       Date:  2015-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.